No benefit of direct renin inhibition in HF in ATMOSPHERE trial - PACE-CME

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
AHA 2024
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
MinuteCE®
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits
Mastering MRA Monitoring: The Key to Success
Mastering MRA Monitoring: The Key to Success
MinuteCE®
Mastering MRA Monitoring: The Key to Success
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits
MinuteCE®
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
0.75 credits 3 episodes
- Gianluigi Savarese, MD
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 credits 3 episodes